Table 3.
Demographic and clinicopathological characteristics of ALK-positive and ALK-negative patients
| ALK-positive (n=92) | ALK-negative (n=320)
|
p value
|
|||
|---|---|---|---|---|---|
| EGFR-positive (n=67) | Wild-type* (n=253) | ALK-positive vs EGFR-positive | ALK-positive vs wild-type | ||
| Age in years, median (range) | 51 (28–78) | 63 (36–90) | 64 (27–87) | <0·0001 | <0·0001 |
| Number of treatments, median (range) | 2 (0–7) | 2 (0–10) | 2 (0–10) | 0·045 | 00·985 |
| Sex | |||||
| Male | 46 (50%) | 23 (34%) | 108 (43%) | 0·054 | 00·270 |
| Female | 46 (50%) | 44 (66%) | 145 (57%) | ||
| Ethnic origin | |||||
| Asian | 6 (7%) | 9 (13%) | 15 (6%)¶ | 0·356 | 00·088 |
| Caucasian | 79 (86%) | 54 (81%) | 231 (92%)¶ | ||
| Other | 7 (8%) | 4 (6%) | 6 (2%)¶ | ||
| Smoking history | |||||
| Never | 70 (76%) | 42 (63%) | 63 (25%) | 1·000† | <0·0001† |
| ≤10 pack-years | 14 (15%) | 20 (30%) | 32 (13%) | ||
| >10 pack-years | 8 (9%) | 5 (7%) | 158 (62%) | ||
| Pathology | |||||
| Adenocarcinoma | 88 (96%) | 66 (99%) | 223 (88%) | 0·398‡ | 00·041‡ |
| NOS | 0 (0%) | 0 (0%) | 15 (6%) | ||
| Squamous-cell | 2 (2%) | 1 (1%) | 10 (4%) | ||
| Large-cell | 2 (2%) | 0 (0%) | 5 (2%) | ||
| Brain metastases§ | |||||
| No | 46 (50%) | 29 (43%) | 147 (58%)¶ | 0·425 | 0·179 |
| Yes | 46 (50%) | 38 (57%) | 105 (42%)¶ | ||
Data are n (%) unless otherwise stated. NOS=not otherwise specified.
*
ALK-negative and EGFR-negative.
†
Never or light smoker vs heavy smoker.
‡
Adenocarcinoma vs other histologies.
§
At any time during the disease course.
¶
Missing information for one patient in these categories, so numbers total 252.